Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김태헌 | * |
dc.date.accessioned | 2016-08-28T10:08:36Z | - |
dc.date.available | 2016-08-28T10:08:36Z | - |
dc.date.issued | 2013 | * |
dc.identifier.issn | 1976-2283 | * |
dc.identifier.other | OAK-9869 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/223529 | - |
dc.description.abstract | Background/Aims: Genotype C is the principal type of hepatitis B virus (HBV) in Koreans and is associated with poor prognosis for peginterferon ?-2a therapy. The efficacy of and compliance to peginterferon ?-2a therapy were investigated in Koreans with hepatitis B in a real clinical setting. Methods: Hepatitis B patients treated with peginterferon ?-2a from 2008 to 2011 at four university hospitals were consecutively enrolled. Results: Eighty-eight patients were enrolled; 67 were hepatitis B e antigen (HBeAg)-positive. The mean treatment period was 36.1±15.2 weeks. In 26.1% of patients, treatment was discontinued due to insufficient antiviral effects and adverse events. At 24 weeks after treatment, 10/42 (23.8%) HBeAg-positive patients achieved both HBV DNA suppression to <2,000 IU/mL and HBeAg loss/seroconversion. For HBeAg-negative patients, 10/13 (76.9%) achieved HBV DNA suppression to <2,000 IU/mL at 24 weeks after treatment. During the follow-up period, 15 (30.6%) of the 49 patients who achieved HBV DNA suppression to 2,000 IU/mL developed a breakthrough HBV DNA level of >2×106 IU/mL. Conclusions: Peginterferon ?-2a therapy in Koreans with hepatitis B in a real clinical setting resulted in a lower virologic response, as compared to Western individuals, but a favorable durability. There is a need to reduce the high rate of premature discontinuation compared to the controlled studies. | * |
dc.language | English | * |
dc.title | The efficacy and safety of peginterferon-α-2a in Korean patients with chronic hepatitis B: A multicenter study conducted in a real clinical setting | * |
dc.type | Article | * |
dc.relation.issue | 2 | * |
dc.relation.volume | 7 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.index | KCI | * |
dc.relation.startpage | 197 | * |
dc.relation.lastpage | 205 | * |
dc.relation.journaltitle | Gut and Liver | * |
dc.identifier.doi | 10.5009/gnl.2013.7.2.197 | * |
dc.identifier.wosid | WOS:000316304300010 | * |
dc.identifier.scopusid | 2-s2.0-84875113234 | * |
dc.author.google | Kwon J.H. | * |
dc.author.google | Kim Y.S. | * |
dc.author.google | Kim S.G. | * |
dc.author.google | Jang J.W. | * |
dc.author.google | Kim T.H. | * |
dc.author.google | Jung Y.K. | * |
dc.author.google | Kwon O.S. | * |
dc.contributor.scopusid | 김태헌(57125156300;57219781484) | * |
dc.date.modifydate | 20240422114851 | * |